Since ATL1102 returned impressive results in a phase II trial in non- ambulant Duchenne muscular dystrophy (naDMD) patients, Antisense Therapeutics (Antisense) has been perfecting its regulatory strategy for the compound. The next naDMD trial, if positive, will be central to a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for naDMD patients. Antisense’s US strategy provides several options and leverages its European Union (EU) activities leading to a New Drug Application to the US Food and Drug Administration (FDA) for naDMD. Now, it comes down to execution.

Biopharmas Hit, but Buying Opportunities Created

Antisense (ANP) & Kazia (KZA), Two Companies To Build Your Biopharma Portfolio Around

The news being reported about the performance of biotechnology has been dour, to say the least, for some time now (Matthew Fox, Markets Insider Article, 7 December 2021; Max Gelman, Endpoints News Article, 26 Jan 2022; Adam Feuerstein et al, Stat News Article, 28 Jan 2022). Those dour articles have been deserved with the iShares Biotechnology Exchange Traded Fund (ETF, NASDAQ: IBB) down 25% and the SPDR® S&P® Biotech ETF (NASDAQ: XBI) is down 45% from their highs. However, those articles are backward looking, and successful investors need to be looking forward.